Integrated Filing — IndAS

General information about company
Scrip Code	500124
NSE Symbol	DRREDDY
MSEI Symbol	NOTLISTED
ISIN	INE089A01031
Name of company	Dr. Reddy's Laboratories Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	09-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	21-Mar-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Multi segment
Description of single segment
Start date and time of board meeting	09-May-2025   09:00:00
End date and time of board meeting	09-May-2025   15:45:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-01-23
Indicate Company website link for updated RPT policy of the Company	https://drreddys.com/cms/sites/default/files/media-library//Policy%20on%20Materiality%20of%20Related%20Party%20Transactions%20and%20Dealing%20with%20Related%20Party%20Transactions%20%281%29.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
As per results attached there are no default on loans and debt securities.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	55629000000	231154000000
	Other income	4144000000	10034000000
	Total income	59773000000	241188000000
2	Expenses
(a)	Cost of materials consumed	9426000000	37997000000
(b)	Purchases of stock-in-trade	5347000000	24399000000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	822000000	-1739000000
(d)	Employee benefit expense	7971000000	32875000000
(e)	Finance costs	311000000	1099000000
(f)	Depreciation, depletion and amortisation expense	2645000000	10394000000
(f)	Other Expenses
1	Impairment of non current assets, net	1036000000	1036000000
2	Other expenses	16597000000	62768000000
	Total other expenses	17633000000	63804000000
	Total expenses	44155000000	168829000000
3	Total profit before exceptional items and tax	15618000000	72359000000
4	Exceptional items	0	0
5	Total profit before tax	15618000000	72359000000
6	Tax expense
7	Current tax	3643000000	17905000000
8	Deferred tax	-32000000	960000000
9	Total tax expenses	3611000000	18865000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	12007000000	53494000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	12007000000	53494000000
17	Other comprehensive income net of taxes	706000000	98000000
18	Total Comprehensive Income for the period	12713000000	53592000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	834000000	834000000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		287732000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	14.41	64.22
	Diluted earnings (loss) per share from continuing operations	14.39	64.13
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	14.41	64.22
	Diluted earnings (loss) per share from continuing and discontinued operations	14.39	64.13
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		As per results attached

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	58654000000
	Capital work-in-progress	21564000000
	Investment property
	Goodwill	853000000
	Other intangible assets	22817000000
	Intangible assets under development	404000000
	Biological assets other than bearer plants
	Investments accounted for using equity method
	Non-current financial assets
	Non-current investments	103105000000
	Trade receivables, non-current	0
	Loans, non-current	14000000
	Other non-current financial assets	8562000000
	Total non-current financial assets	111681000000
	Deferred tax assets (net)	1244000000
	Other non-current assets	662000000
	Total non-current assets	217879000000
2	Current assets
	Inventories	45758000000
	Current financial asset
	Current investments	28830000000
	Trade receivables, current	59590000000
	Cash and cash equivalents	3197000000
	Bank balance other than cash and cash equivalents	6571000000
	Loans, current	0
	Other current financial assets	1449000000
	Total current financial assets	99637000000
	Current tax assets (net)
	Other current assets	19635000000
	Total current assets	165030000000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	382909000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	834000000
	Other equity	287732000000
	Total equity attributable to owners of parent	288566000000
	Non controlling interest
	Total equity	288566000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	765000000
	Total non-current financial liabilities	765000000
	Provisions, non-current	54000000
	Deferred tax liabilities (net)	5154000000
	Deferred government grants, Non-current	0
	Other non-current liabilities	1852000000
	Total non-current liabilities	7825000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	33855000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	210000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	19721000000
	Total Trade payable	19931000000
	Other current financial liabilities	21537000000
	Total current financial liabilities	75323000000
	Other current liabilities	7006000000
	Provisions, current	3395000000
	Current tax liabilities (Net)	794000000
	Deferred government grants, Current
	Total current liabilities	86518000000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	94343000000
	Total equity and liabilites	382909000000
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block
Textual Information(1)	As per results attached

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	a) Pharmaceutical Services and Active Ingredients	9140000000	33904000000
2	b) Global Generics	48287000000	204602000000
3	c) Others	45000000	1410000000
	Total Segment Revenue	57472000000	239916000000
	Less: Inter segment revenue	1843000000	1843000000
	Revenue from operations	55629000000	231154000000
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	a) Pharmaceutical Services and Active Ingredients	256000000	353000000
2	b) Global Generics	15231000000	69966000000
3	c) Others	47000000	1419000000
	Total Profit before tax	15534000000	71738000000
	i. Finance cost	311000000	311000000
	ii. Other Unallocable Expenditure net off Unallocable income	-395000000	-395000000
	Profit before tax	15618000000	72359000000
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	a) Pharmaceutical Services and Active Ingredients	0	0
2	b) Global Generics	0	0
3	c) Others	0	0
	Total Segment Asset	0	0
	Un-allocable Assets	0	0
	Net Segment Asset	0	0
4	Segment Liabilities
	Segment Liabilities
1	a) Pharmaceutical Services and Active Ingredients	0	0
2	b) Global Generics	0	0
3	c) Others	0	0
	Total Segment Liabilities	0	0
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	0	0
	Disclosure of notes on segments	Textual Information(2)

Text Block
Textual Information(2)	As per results attached

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will not be reclassified subsequently to profit or loss	-103000000	-103000000
	Total Amount of items that will not be reclassified to profit and loss	-103000000	-103000000
2	Income tax relating to items that will not be reclassified to profit or loss	-26000000	-26000000
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified subsequently to profit or loss	1046000000	234000000
	Total Amount of items that will be reclassified to profit and loss	1046000000	234000000
4	Income tax relating to items that will be reclassified to profit or loss	263000000	59000000
5	Total Other comprehensive income	706000000	98000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			72359000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			1099000000
	Adjustments for decrease (increase) in inventories			-8340000000
	Adjustments for decrease (increase) in trade receivables, current			-13451000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-81000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			-517000000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			0
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			10394000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			1036000000
	Adjustments for provisions, current			2771000000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-116000000
	Adjustments for dividend income			0
	Adjustments for interest income			4825000000
	Adjustments for share-based payments			382000000
	Adjustments for fair value losses (gains)			-3128000000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			428000000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			103000000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-14245000000
	Net cash flows from (used in) operations			58114000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			15864000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			42250000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			67541000000
	Other cash receipts from sales of equity or debt instruments of other entities			255044000000
	Other cash payments to acquire equity or debt instruments of other entities			224740000000
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			323000000
	Purchase of property, plant and equipment			23393000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			104000000
	Purchase of intangible assets			1374000000
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			3998000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			603000000
	Net cash flows from (used in) investing activities	-56976000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			193000000
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			1389000000
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			25840000000
	Repayments of borrowings			0
	Payments of lease liabilities			281000000
	Dividends paid			6662000000
	Interest paid			1794000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			15907000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			1181000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			2000000
	Net increase (decrease) in cash and cash equivalents			1183000000
	Cash and cash equivalents cash flow statement at beginning of period			2014000000
	Cash and cash equivalents cash flow statement at end of period			3197000000